CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease: Favorable results with acceptable toxicity

Julie M. Vose, Philip J. Bierman, James R. Anderson, Dennis Weisenburger, Daniel F. Moravec, Scot Sorensen, Mark Hutchins, Monroe D. Dowling, David Howe, John Okerbloom, Robert M. Langdon, George K. Bascom, William Packard, Warren Pevnick, James O. Armitage

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group. One hundred patients, 87 with newly diagnosed Hodgkin's disease and 13 who relapsed after receiving previous radiation therapy, were treated with this regimen between 1982 and 1989. Complete remissions (CRs) were obtained in 88 of 100 patients (88%), and there have been a total of eight relapses. The overall 3-year failure-free survival was 76%, with good-prognosis patients (ie, Karnofsky performance status ≥ 80) having a 3-year failure-free survival of 87%. Toxicity with this regimen was minimal, with neutropenic fevers reported in 13% of the patient population, moderate alopecia in 5%, and mild to moderate nausea and vomiting in 11 % of the patients. As primary-induction therapy for Hodgkin's disease, CHLVPP is an effective regimen with a high patient acceptance profile.

Original languageEnglish (US)
Pages (from-to)1421-1425
Number of pages5
JournalJournal of Clinical Oncology
Volume9
Issue number8
DOIs
StatePublished - 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease: Favorable results with acceptable toxicity'. Together they form a unique fingerprint.

  • Cite this

    Vose, J. M., Bierman, P. J., Anderson, J. R., Weisenburger, D., Moravec, D. F., Sorensen, S., Hutchins, M., Dowling, M. D., Howe, D., Okerbloom, J., Langdon, R. M., Bascom, G. K., Packard, W., Pevnick, W., & Armitage, J. O. (1991). CHLVPP chemotherapy with involved-field irradiation for hodgkin's disease: Favorable results with acceptable toxicity. Journal of Clinical Oncology, 9(8), 1421-1425. https://doi.org/10.1200/JCO.1991.9.8.1421